Profile data is unavailable for this security.
About the company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
- Revenue in USD (TTM)0.00
- Net income in USD-614.93m
- Incorporated2020
- Employees105.00
- LocationSummit Therapeutics Inc2882 Sand Hill Road, Suite 106MENLO PARK 94025United StatesUSA
- Phone+1 (650) 460-8308
- Fax+1 (302) 655-5049
- Websitehttps://www.smmttx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avidity Biosciences Inc | 9.56m | -212.22m | 2.24bn | 253.00 | -- | 3.73 | -- | 233.88 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Vericel Corp | 197.52m | -3.18m | 2.24bn | 314.00 | -- | 9.79 | 1,428.26 | 11.33 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.28bn | 445.00 | -- | 3.45 | -- | 29.01 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.34bn | 226.00 | -- | 13.46 | -- | 30.27 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Corcept Therapeutics Incorporated | 482.38m | 106.14m | 2.39bn | 352.00 | 24.10 | 4.69 | 22.28 | 4.95 | 0.9542 | 0.9542 | 4.32 | 4.90 | 0.8007 | 0.9374 | 13.37 | 1,370,384.00 | 17.62 | 21.17 | 20.65 | 23.85 | 98.66 | 98.52 | 22.00 | 27.23 | 4.31 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.40bn | 445.00 | -- | 2.26 | -- | 7.25 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Merus NV | 43.95m | -154.94m | 2.41bn | 172.00 | -- | 6.66 | -- | 54.82 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| CG Oncology Inc | 204.00k | -67.80m | 2.43bn | 61.00 | -- | -- | -- | 11,893.26 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Janux Therapeutics Inc | 8.08m | -58.29m | 2.48bn | 64.00 | -- | 6.44 | -- | 306.52 | -1.34 | -1.34 | 0.1837 | 7.44 | 0.0217 | -- | -- | 126,296.90 | -15.66 | -- | -16.31 | -- | -- | -- | -721.18 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Summit Therapeutics Inc | 0.00 | -614.93m | 2.51bn | 105.00 | -- | 32.24 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Celldex Therapeutics, Inc. | 6.88m | -141.43m | 2.55bn | 160.00 | -- | 5.16 | -- | 370.81 | -2.91 | -2.91 | 0.1421 | 7.68 | 0.0168 | -- | 4.63 | 43,018.75 | -34.56 | -29.65 | -36.80 | -31.42 | -- | -- | -2,054.76 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Neogen Corp | 929.24m | 1.57m | 2.63bn | 2.64k | 1,683.77 | 0.8358 | 22.31 | 2.83 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| Hims & Hers Health Inc | 872.00m | -23.55m | 2.66bn | 1.05k | -- | 7.70 | -- | 3.05 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 2.66bn | 497.00 | -- | 7.36 | -- | 10.67 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
Data as of Apr 18 2024. Currency figures normalised to Summit Therapeutics Inc's reporting currency: US Dollar USD
3.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 8.64m | 1.23% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 6.69m | 0.95% |
| Geode Capital Management LLCas of 31 Dec 2023 | 3.09m | 0.44% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.46m | 0.35% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 1.10m | 0.16% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 953.85k | 0.14% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 649.09k | 0.09% |
| Steward Partners Investment Advisory LLCas of 31 Dec 2023 | 600.00k | 0.09% |
| ALPS Advisors, Inc.as of 31 Dec 2023 | 532.41k | 0.08% |
| Teachers Advisors LLCas of 31 Dec 2023 | 497.48k | 0.07% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
